Skip to main content
Move the World.
coronavirus vaccine

Lead Image © Bloomicon.

As the novel coronavirus 2019-nCoV proliferates in China and spreads (to a much lesser extent) abroad — even reaching your correspondent's home base of Chicago; he's feeling fine, don't worry — the race is on for a new vaccine.

But creating a new vaccine is a laborious and expensive process, and when faced with a brand-new virus, the challenges are increased. Scientists must first understand what they are up against, and then they need to produce vast quantities of the ingredients necessary for a vaccine. Finally, even if it all works, the financial benefits can be minimal, leading many companies to shun investing in vaccines for emerging or uncommon diseases.

Vaccines work by priming the immune system to make antibodies for a particular disease. These large, y-shaped proteins then stick into the virus, disabling it or marking it for death by white blood cells. Vaccines use antigens, the protein signature of a virus, to stimulate the body to produce antibodies. Once the immune system has made them, the body will "remember" them and release a flood again as soon as the real virus attacks.

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), wants vaccines for the Wuhan coronavirus to be ready for trial in three months. This is a monumental ask. But a handful biotech companies — with support from the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership which looks to accelerate vaccine development — are stepping up.

One of those companies, Cambridge-based Moderna Therapeutics, is harnessing the power of mRNA-based vaccines.

RNA vaccines use mRNA — essentially, cellular instructions translated from DNA — to tell the body's own cells to make antigens. Since RNA vaccines don't use the actual virus (or parts of it) to make the antigens, there is no need to grow and store huge quantities of them — an extremely expensive and time-consuming process that must be done specially for every disease's vaccine.

More importantly, mRNA is written in a simple genetic code. Researchers only need the genetic code of a pathogen to create potential mRNA antigens. It's basically a plug-and-play model, which means RNA vaccines can be created in bulk: cheaper, faster, and with standardized methods. It also means you can rapidly shift production to a new pathogen or new antigen candidate by inserting a new code.

Like, say, a novel coronavirus.

Moderna already has an animal-tested vaccine for Middle East respiratory syndrome (MERS), which is caused by a similar coronavirus. Theoretically, Moderna can substitute the code for their MERS vaccine with one from 2019-nCoV to create the new vaccine. "It was a really, really hard scientific challenge to make the first one, but once you get the first one working, the next one becomes really easy: You get the sequence, and this is just another one," Stéphane Bancel, the CEO of Moderna, told Science Mag.

If the vaccine works, Moderna could prepare vast amounts of it: up to 100 million doses a year, if it dedicated all its resources to it, according to Bancel. This would be orders of magnitude greater and faster than traditional vaccine development, and such a feat would prove RNA vaccines' ability to be rapidly developed, scaled, and deployed.

If it works. Trials are expected to begin in three months.

Up Next

Genetics
A “Self-Deleting” Gene Drive to End Mosquito-Borne Diseases
gene drive mosquito
Genetics
A “Self-Deleting” Gene Drive to End Mosquito-Borne Diseases
A gene drive designed to remove itself from an insect population after a few generations could help bring an end to mosquito-borne diseases.

A gene drive designed to remove itself from an insect population after a few generations could help bring an end to mosquito-borne diseases.

Insects
A French Company Is Building the World’s Biggest Insect Factory Farm
insect farming
Insects
A French Company Is Building the World’s Biggest Insect Factory Farm
Ÿnsect is building the world’s largest insect farming facility in Amiens, France. The mealworms grown there may end up feeding your pets and the salmon on your plate.

Ÿnsect is building the world’s largest insect farming facility in Amiens, France. The mealworms grown there may end up feeding your pets and the salmon on your plate.

Digital Detectives
An Invite to Hack Voting Machines
voting machines
Digital Detectives
An Invite to Hack Voting Machines
Voting machines may have security vulnerabilities, so the largest supplier is inviting pro hackers to find them.

Voting machines may have security vulnerabilities, so the largest supplier is inviting pro hackers to find them.

Music
This Algorithm Just Generated 68 Billion Unique Melodies
melodies
Music
This Algorithm Just Generated 68 Billion Unique Melodies
Two musicians built an algorithm that could write every melody in the popular music range — and then released the melodies into the public domain.

Two musicians built an algorithm that could write every melody in the popular music range — and then released the melodies into the public domain.

Below the Surface
The Fleet of Underwater Drones Probing Earth’s Interior
underwater drones
Below the Surface
The Fleet of Underwater Drones Probing Earth’s Interior
The Earth’s interior may be the last wild frontier, but not for long. These underwater drones are scanning the ocean to create a 3D model of its internal dynamics.

The Earth’s interior may be the last wild frontier, but not for long. These underwater drones are scanning the ocean to create a 3D model of its internal dynamics.

Seachange
The Fight to End Illegal Logging
illegal logging
Seachange
The Fight to End Illegal Logging
Citizen scientists are collecting tree samples to build a genetic database that will help identify the origins of stolen lumber and stop illegal logging.

Citizen scientists are collecting tree samples to build a genetic database that will help identify the origins of stolen lumber and stop illegal logging.

Superhuman
Can Genetically Modified Pigs Be the Key to Treating Rare Diseases?
Can Genetically Modified Pigs Be the Key to Treating Rare Diseases?
Watch Now
Superhuman
Can Genetically Modified Pigs Be the Key to Treating Rare Diseases?
When it comes to rare diseases, doctors often don’t have enough patients to determine the effectiveness of various treatments. Now, scientists are breeding pigs with the same genetic code as people with a disease in order to create a pool of test "patients" unlike any before.
Watch Now

There are thousands of diseases known to modern medicine without any cure or treatment. Many are too rare to get much attention from doctors, governments, or drug companies. But the gene editing tool CRISPR is offering hope for people with rare and hard to study diseases, like the genetic disease known as NF1. There are tens of thousands of Americans with this tumor-causing nerve disease, but because it has over 4,000...

Coded
Meet the Programmer Who Defied the FBI
Meet the Programmer Who Defied the FBI
Coded
Meet the Programmer Who Defied the FBI
Ladar Levison spent 10 years building his business, then destroyed it all in one night when the FBI came knocking.
By Mike Riggs

Ladar Levison spent 10 years building his business, then destroyed it all in one night when the FBI came knocking.